John Pagliuca

Consumers of life sciences products are reluctant customers, and this reluctance can turn into non-compliance. Organizations and providers need to understand patients at a human level, and what will motivate them to stay with a treatment plan, writes John Pagliuca.

There is a tremendous, untapped market of undiagnosed patients for a variety of conditions, writes John Pagliuca. But how do you identify them when they are essentially hidden from view through conventional means?